The drug rademikibart showed improvements in lung function and asthma control for adults with moderate to severe persistent asthma in a phase 2b trial. Patients experienced greater lung function improvements when receiving rademikibart every 2 weeks compared to those who received a placebo. The drug was generally well tolerated and led to significant improvements in pre-bronchodilator FEV1 at both the 150 mg and 300 mg doses. At week 24, rademikibart patients also demonstrated significant improvements in asthma control and a lower number of total exacerbations. The drug is progressing to phase 3 trials with potential for transformational therapy.
Source link
Rademikibart improves lung function in moderate to severe asthma
